SNGX

SOLIGENIX, INC. - 10-Q Summary (Period Ended September 30, 2010)

Business Context and Reporting Period

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products for cancer treatment side effects, gastrointestinal diseases, and biodefense. The company operates two segments: BioTherapeutics (lead product orBec for GI Graft-versus-Host Disease) and BioDefense (ricin toxin vaccine and radiation injury programs). This report covers the quarterly period ended September 30, 2010.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term debt. Current liabilities totaled $1,530,297, primarily accounts payable ($1,491,538). Management estimates current cash will suffice for operations into the second quarter of 2012.

Material Changes vs. Prior Period

• Revenue: Increased 1% year-over-year (9 months) to $1.64 million, driven by NIH grant revenues.
• Gross Profit: Decreased 36% to $238,693 due to higher costs associated with grant-funded research and a $30,211 inventory write-off for expired NPAP product.
• Net Loss: Decreased slightly by 3% to $5.45 million, primarily due to reduced General and Administrative (G&A) expenses.
• Operating Expenses: Total operating expenses decreased 5% to $5.69 million. G&A expenses dropped 17% due to reduced compensation and severance costs. R&D expenses remained relatively flat, decreasing 1%.
• Stock-Based Compensation: Increased significantly in the quarter (510% for R&D, 105% for G&A) due to a company-wide grant issued in July 2010.
• Intangible Assets: A one-time patent write-off of $378,501 was recorded related to the abandonment of the botulinum toxin vaccine license.

Guidance, Outlook, and Risks

Outlook: Management believes cash on hand, combined with grant proceeds and potential milestone payments, is sufficient to fund operations into Q2 2012. The company has approximately $8.6 million in active grant funding available and $7.7 million in capacity under its Fusion Capital equity facility.

Key Developments:

• orBec: The pivotal Phase 3 confirmatory trial for acute GI GVHD is ongoing, with completion expected in H2 2011. A $1 million milestone payment was received from partner Sigma-Tau upon patient enrollment.
• SGX201: Phase 1/2 trial for acute radiation enteritis is enrolling; FDA Fast Track designation received.
• RiVax: Phase 1B trial enrollment complete; data expected H1 2011.

Risks and Contingencies:

• Liquidity: Continued dependence on equity financing and government grants. No assurance exists that additional capital can be raised at favorable terms.
• Regulatory: Success depends on FDA approval of orBec following the Phase 3 trial. Previous NDA was not approved in 2007.
• Commitments: Approximately $932,000 committed to Numoda Corporation for the Phase 3 trial execution.
• Tax: Full valuation allowance recorded against net deferred tax assets due to cumulative losses.

Investor Verification Checklist

• Cash Runway: Verify the timeline for cash sufficiency (projected to Q2 2012) against actual burn rates and upcoming capital needs.
• Phase 3 Trial Status: Monitor enrollment progress and interim data for the orBec confirmatory trial, which is critical for future commercialization.
• Grant Funding: Confirm the status of the $8.6 million in active grant funding and the likelihood of securing additional government support.
• Dilution Risk: Review the impact of the June 2010 private placement (28.8M shares) and ongoing equity line usage on shareholder dilution.
• Patent Portfolio: Assess the impact of the $378,501 botulinum toxin patent write-off on the overall IP strategy.